NCT06588972 is a Phase 2 clinical trial of Medium Chain Triglyceride solution in OSTEOARTHRITIS OF THE KNEE, sponsored by Federal University of Latin American Integration.

Who is sponsoring NCT06588972?

NCT06588972 is sponsored by Federal University of Latin American Integration.

What drugs are being tested in NCT06588972?

Interventions in NCT06588972: Medium Chain Triglyceride solution, Cannabis Sativa.

What condition does NCT06588972 study?

NCT06588972 studies OSTEOARTHRITIS OF THE KNEE.

Is NCT06588972 still recruiting?

NCT06588972 is currently completed. Last updated 2 July 2025.

Last reviewed 2025-07-02 · How we verify

NCT06588972

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analgesic Effects of a Treatment With Cannabis Sativa Extract in Patients With Knee Osteoarthritis - CANOA (Cannabis for Osteoarthritis)

Completed Phase 2 Last updated 2 July 2025

What this trial tests

Phase 2 trial testing Medium Chain Triglyceride solution in OSTEOARTHRITIS OF THE KNEE in 45 participants. Completed in 12 October 2024.

Timeline

1 January 2024

Primary endpoint
10 October 2024

12 October 2024

Quick facts

Lead sponsor	Federal University of Latin American Integration
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	45
Start date	1 January 2024
Primary completion	10 October 2024
Estimated completion	12 October 2024
Sites	1 location across Brazil

Drugs / interventions tested

Medium Chain Triglyceride solution
Cannabis Sativa — full drug profile →

Conditions studied

OSTEOARTHRITIS OF THE KNEE — all drugs for OSTEOARTHRITIS OF THE KNEE →

Sponsor

Federal University of Latin American Integration

Who can join

Adults 30 to 70, any sex, with OSTEOARTHRITIS OF THE KNEE. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Osteoarthritis (OA) is the most prevalent joint disease in humans, often causing disability in affected individuals, especially the elderly. OA is characterized by mechanical joint pain, crepitus and short-term post-immobilization stiffness. OA pain has a variable pathophysiology and, despite the many pharmacological options available, its treatment is often ineffective and has significant side effects. The search for more effective and safer treatments is therefore essential in the field of OA. Among the possible treatments are substances derived from cannabis. Cannabis plants have been used for various purposes by humankind for thousands of years. Its best-known species, Cannabis sativa, has more than a hundred substances called cannabinoids or, more specifically, phytocannabinoids, the most important of which is cannabidiol (CBD). Although many pre-clinical studies indicate the usefulness of phytocannabinoids, clinical evidence for their application is currently scarce. Therefore, this project aims to investigate the effects of a CBD-rich extract of Cannabis sativa on the pain of patients with knee OA, as well as the possible adverse events of this treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects and safety of a CBD-rich <i>Cannabis sativa</i> oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial - CANOA - cannabis for osteoarthritis.
Mojoli A, Haider O, Fakih Y, Luz Gonçalves MV, et al · · 2025 · cited 1× · PMID 41487518 · DOI 10.3389/fphar.2025.1657065

Verify or expand the search:

Other Federal University of Latin American Integration trials

Trials by the same sponsor.

NCT07498023 — EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PIL · Phase 1, PHASE2 · active not recruiting
NCT07091747 — Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's D · Phase 1, PHASE2 · active not recruiting
NCT06898606 — Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression · Phase 1, PHASE2 · recruiting
NCT06570928 — Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06588972 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federal University of Latin American Integration
Last refreshed: 2 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06588972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing